Navigation Links
IRSF awards $1.5 million for novel basic and translational research programs
Date:1/14/2013

Cincinnati, (OH) - The International Rett Syndrome Foundation (IRSF) broadened and intensified its efforts to produce treatments for Rett syndrome and related disorders, announcing today that it is awarding another $1.5M to support 18 new grants at leading global research institutions. In 2012, IRSF invested nearly $4M in high-quality, peer-reviewed research grants that give promise to advancing treatment strategies of Rett syndrome and other MECP2 disorders. The grants awarded today are designed to study a variety of diverse topics from basic discovery science and disease pathology to testing compounds and developing outcome measures for Rett syndrome. IRSF is the world's largest private source of funding for biomedical and clinical Rett syndrome research. Since 1998, IRSF has funded $30M in innovative research grants which have produced critical breakthroughs to advance the understanding of this neurological condition.

IRSF funds pioneering studies in Basic Research that aim to discover new avenues that may be amendable to novel therapies. IRSF also seeks to bridge the critical translational funding gap by investing in Translational Research that includes both pre-clinical and clinical studies. In an effort to recruit future Rett researchers, IRSF creates fellowships to outstanding post-doctoral research scientists and clinical scientists.

The awarded basic research projects cover discovery topics from epigenetics and gene regulation to understanding pathways and other neuronal cell types in Rett syndrome. Together, these studies will allow for identification of new therapeutic targets in Rett syndrome. The second round of translational grants is focused on gene therapy approaches, development and testing of potential therapeutic compounds, and development of outcome measures in humans that will be used in future clinical studies.

"This year's call for proposals produced our largest number of outstanding quality grant applications to IRSF in the history of the organization," commented Steven Kaminsky, PhD, the Chief Science Officer of IRSF. "The astounding response from the science community to our call bodes well for Rett syndrome research and illustrates the growing number of researchers exploring the biology surrounding Rett syndrome and possible treatments that will modify its course." Dr. Kaminsky added, "As more and more fundamental discoveries are made and translated into pre-clinical and clinical trials each year, we get closer to our goal of modifying the biology surrounding Rett syndrome and improving the lives of our Rett patients and their families. With the help of a superb group of reviewers, we have built a plan that funds the best of the best. We look forward to working with these investigators as we continue to push our mission to reverse Rett syndrome."

New Translational Research Awards

  • Kevin Foust, PhD, Ohio State University
    AAV Gene Therapy for MECP2 Duplication
  • Steven Gray, PhD, University of North Carolina at Chapel Hill
    MECP2 gene transfer using novel RTT-specific rAAV vectors
  • Daniel Glaze, MD, Baylor College of Medicine
    Autonomic Nervous System (ANS) Dysregulation in Rett Syndrome: Objective Measures through Pupillometry and ANS Questionnaire
  • Kevin Jones, PhD, University of Colorado-Boulder
    A Screen for Compounds that Regulate BDNF Expression
  • Jay Shapiro, MD, Kennedy Krieger Institute
    Treatment of Osteoporosis in Murine Rett Syndrome Models: A Comparison of Zoledronic Acid vs. Teriparitide on Osteoblast Function, Gene Expression and Bone Mass
  • Dag Yasui, PhD, University Of California-Davis
    Investigation of CHRNA7 Ligands as Potential Rett Therapies

New Basic Research Awards-Regular Research Grants

  • Chinfei Chen, MD, PhD, Children's Hospital Boston Testing for Reversibility of Sensory System Circuitopathy in Mouse Models for RTT
  • Yvonne Nsokika Fondufe-Mittendorf, PhD, University of Kentucky-Lexington
    The Epigenetic Control of Gene Expression by MeCP2
  • Ali Khoshnan, PhD, California Institute of Technology
    The Role of IKK Signaling Pathway in Rett Syndrome
  • Charlotte Kilstrup-Nielsen, PhD, University of Insubria
    Investigation of the Importance of a Hitherto Uncharacterized MeCP2 Phospho-isoform for Neuronal Morphogenesis and Chromatin Related Functions
  • David Lieberman, MD, PhD, University of California, San Diego
    A Proteomics Based Approach to Restore Bidirectional Homeostatic Plasticity in MeCP2 Deficient Neurons In Vitro and In Vivo
  • Alysson Muotri, PhD, University of California, San Diego
    Contribution of Human Astrocytes to Rett Syndrome
  • Michelle Olsen, PhD, University of Alabama at Birmingham
    Altered K+ Ion and Glutamate Homeostasis in Rett Syndrome
  • Beth Stevens, PhD, Children's Hospital Boston
    Role of Microglia at Synapses in Rett Syndrome

New Mentored Training Fellowships

  • Miao He, PhD, Cold Spring Harbor Laboratory
  • A New Mouse Model for Conditional MeCP2 Inactivation and Reactivation
  • Roberto Herai, PhD, University of California, San Diego
    A Comprehensive Analyses of Transcriptomic and Proteomic Expression in Rett Syndrome Neurons
  • Yun Li, PhD, Whitehead Institute For Biomedical Research
    Modeling Rett Syndrome Using TALEN Technology in Human Pluripotent Stem Cells
  • Annarita Patrizi, PhD, Children's Hospital Boston
    Rescuing Misregulation of NMDA Receptor Subunits in Rett Syndrome

"The possibility of new treatments for Rett syndrome increases as our research program broadens and intensifies," said Dr. Kaminsky. "I would like to thank our Board and our donors for their demonstrated commitment to advancing the best science in the community."
'/>"/>

Contact: Kathryn Kissam
804-519-6231
International Rett Syndrome Foundation
Source:Eurekalert

Related medicine news :

1. Biophysical Society announces winners of 2013 Minority Affairs Committee travel awards
2. Author, Speaker, Healer, Nina Brown Recognized by 2012 USA Best Book Awards
3. International Essential Tremor Foundation Awards Scholarship
4. Year’s Recap Includes Office Relocation and Awards for Permanent Makeup Doctor
5. Patient-Centered Outcomes Research Institute announces 2 awards to Group Health
6. Celldance 2012 video awards, the Cell Oscars, roll out tiny red carpet
7. IOF Young Investigator Awards in Kuala Lumpur recognize high-quality research abstracts
8. TAMEST announces recipients of the 2013 Edith and Peter ODonnell Awards
9. AHA awards Loyola more than $60,000 for cardiac research
10. Templeton Foundation awards grant for meditation research
11. NIH awards Georgia malaria research consortium up to $19.4 million contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling ... handle, you are not alone. According to the Center for Disease Control and Prevention ... type 2 diabetes and certain types of cancer, some of the leading causes of ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical ... heart failure, today announced that it intends to offer shares ... an underwritten public offering.  The offering is subject to market ... to whether or when the offering may be completed, or ...   --> --> Roth ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
(Date:2/9/2016)... This TforG report includes the Surgical Procedures Database with ... in South Korea . To add ... written and numerical analysis on the current trends, size, ... latest reforms of the local Healthcare system are clearly ... The report helps businesses gain a unique insight into ...
Breaking Medicine Technology: